443 related articles for article (PubMed ID: 23104222)
1. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Osako T; Ito Y; Ushijima M; Takahashi S; Tokudome N; Sugihara T; Iwase T; Matsuura M; Hatake K
Cancer Chemother Pharmacol; 2009 Apr; 63(5):865-71. PubMed ID: 18670777
[TBL] [Abstract][Full Text] [Related]
5. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
Jassem J; Fein L; Karwal M; Campone M; Peck R; Poulart V; Vahdat L
Breast; 2012 Feb; 21(1):89-94. PubMed ID: 21937232
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
7. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.
Blum JL; Kohles J; McKenna E; Scotto N; Hu S; Odom D; Kaye JA; Glück S
Breast Cancer Res Treat; 2011 Jan; 125(2):431-9. PubMed ID: 21042933
[TBL] [Abstract][Full Text] [Related]
8. Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
Kotsori AA; Noble JL; Ashley S; Johnston S; Smith IE
Breast; 2010 Oct; 19(5):377-81. PubMed ID: 20392643
[TBL] [Abstract][Full Text] [Related]
9. Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Kamal AH; Camacho F; Anderson R; Wei W; Balkrishnan R; Kimmick G
Breast Cancer Res Treat; 2012 Jul; 134(1):371-8. PubMed ID: 22460617
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
[TBL] [Abstract][Full Text] [Related]
11. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
[TBL] [Abstract][Full Text] [Related]
12. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
Fornier M
Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979
[TBL] [Abstract][Full Text] [Related]
13. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.
Ambros T; Zeichner SB; Zaravinos J; Montero AJ; Ahn E; Aruna M; Kronish L; Mahtani RL; Vogel CL
Breast Cancer Res Treat; 2014 Jul; 146(1):7-14. PubMed ID: 24899084
[TBL] [Abstract][Full Text] [Related]
15. A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.
Seidman AD; Chan S; Wang J; Zhu C; Xu C; Xu B
Oncologist; 2014 May; 19(5):443-52. PubMed ID: 24705980
[TBL] [Abstract][Full Text] [Related]
16. Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
Taguchi T; Yamamoto D; Masuda N; Oba K; Nakayama T; Nagata T; Nomura M; Yoshidome K; Yoshino H; Matsunami N; Miyashita M; Furuya Y; Ishida T; Wakita K; Sakamoto J; Noguchi S;
Cancer Chemother Pharmacol; 2013 Mar; 71(3):741-7. PubMed ID: 23334260
[TBL] [Abstract][Full Text] [Related]
17. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
[TBL] [Abstract][Full Text] [Related]
18. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
Venturini M; Paridaens R; Rossner D; Vaslamatzis MM; Nortier JW; Salzberg M; Rodrigues H; Bell R
Oncology; 2007; 72(1-2):51-7. PubMed ID: 18004077
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
Pierga JY; Fumoleau P; Brewer Y; Zelek L; Martin D; Turpin FL; Goudier MJ; Gil-Delgado M; Baticle JL; Namer M; Chollet P; Sutherland W; Barats JC;
Breast Cancer Res Treat; 2004 Nov; 88(2):117-29. PubMed ID: 15564795
[TBL] [Abstract][Full Text] [Related]
20. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
